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Squamous cell carcinoma of head and neck (HNSCC)
cells express low HLA class I and antigen processing
machinery (APM) components, such as transporter
TAP-1/2, which is associated with the reduced sensitivity
to cytotoxic T lymphocyte (CTL) mediated lysis. Epider-
mal growth factor receptor (EGFR) is overexpressed in
HNSCC and is associated with the poor prognosis. FDA
approved anti-EGFR blockade mAb cetuximab inhibits
HNSCC proliferation, and induces EGFR-specific CTL.
However, the molecular mechanism(s) underlying the
EGFR-specific CTL recognition of HNSCC in the thera-
peutic efficacy of anti-EGFR mAb is still emerging. We
show that cetuximab or EGFR knockdown enhanced
expression of HLA class I antigens, which is associated
with the EGFR expression level on HNSCC. These find-
ings were validated in a prospective trial of neoadjuvant
cetuximab therapy. Interestingly, upregulation of HLA-B/
C alleles were more pronounced than HLA-A alleles
after cetuximab or EGFR knockdown treatment. EGFR
signaling blockade or EGFR depletion also enhanced IFN
gamma receptor (IFNAR) on HNSCC and augmented
induction of HLA class I and TAP-1/2 caused by IFN
gamma treatment. Cetuximab or EGFR knockdown
enhanced the level of HLA class I, STAT-1, TAP-1/2 in
a STAT-1+/+ cell line but not in STAT-1-/- cell line,
documenting the STAT-1 dependence of this effect. We
also found that Src homology domain-containing phos-
phatase 2 (SHP-2), which is downstream of EGFR and
also overexpressed in SCCHN, can suppress the immu-
nostimulatory effect of cetuximab treatment on HLA
class I/STAT-1 upregulation, and dual targeting of EGFR
and SHP-2 co-operates in the most efficient reversal of
immune escape phenotype. In addition, cetuximab-based
EGFR inhibition and SHP-2 depletion enhanced the
recognition of HNSCC cells by EGFR 853-861 specific
CTL, and enhanced surface presentation of non-EGFR
TA, such as MAGE-3 271-279 , indicating that a broad
tumor antigen repertoire is processed and presented by
HLA/APM upregulation. These findings elucidate a
novel immune escape mechanism associated with EGFR
signaling through STAT1 suppression and the reversal
with cetuximab, which may provide additional targets for
on-going mAb-based immunotherapy.
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